NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Solid Tumor
Related studies linked through entity extraction aliases.
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
- Status
- COMPLETED
- Phase
- PHASE1
Tepotinib in Solid Tumors Harboring MET Alterations
- Status
- UNKNOWN
- Phase
- PHASE2
Expanded Access for Marizomib
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
- Status
- TERMINATED
- Phase
- PHASE2
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
- Status
- COMPLETED
- Phase
- PHASE1
Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
- Status
- TERMINATED
- Phase
- PHASE1
IMP4297 DDI (Drug-Drug Interaction)Trial in Healthy Male Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE2
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE2
Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
- Status
- TERMINATED
- Phase
- PHASE1
Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
- Status
- UNKNOWN
- Phase
- PHASE1